{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:32:00Z","timestamp":1792787520541,"version":"4.5.0"},"reference-count":38,"publisher":"Wiley","license":[{"start":{"date-parts":[[2014,4,30]],"date-time":"2014-04-30T00:00:00Z","timestamp":1398816000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"funder":[{"name":"Vifor (International) AG, Switzerland"},{"name":"Beate Rzychon"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy Research and Practice"],"published-print":{"date-parts":[[2014,4,30]]},"abstract":"<jats:p>Since anthracycline-induced cardiotoxicity (AIC), a complication of anthracycline-based chemotherapies, is thought to involve iron, concerns exist about using iron for anaemia treatment in anthracycline-receiving cancer patients. This study evaluated how intravenous ferric carboxymaltose (FCM) modulates the influence of iron deficiency anaemia (IDA) and doxorubicin (3\u20135\u2009mg per kg body weight [BW]) on oxidative\/nitrosative stress, inflammation, and cardiorenal function in spontaneously hypertensive stroke-prone (SHR-SP) rats. FCM was given as repeated small or single total dose (15\u2009mg iron per kg BW), either concurrent with or three days after doxorubicin. IDA (after dietary iron restriction) induced cardiac and renal oxidative stress (markers included malondialdehyde, catalase, Cu,Zn-superoxide dismutase, and glutathione peroxidase), nitrosative stress (inducible nitric oxide synthase and nitrotyrosine), inflammation (tumour necrosis factor-alpha and interleukin-6), and functional\/morphological abnormalities (left ventricle end-diastolic and end-systolic diameter, fractional shortening, density of cardiomyocytes and capillaries, caveolin-1 expression, creatinine clearance, and urine neutrophil gelatinase-associated lipocalin) that were aggravated by doxorubicin. Notably, iron treatment with FCM did not exacerbate but attenuated the cardiorenal effects of IDA and doxorubicin independent of the iron dosing regimen. The results of this model suggest that intravenous FCM can be used concomitantly with an anthracycline-based chemotherapy without increasing signs of AIC.<\/jats:p>","DOI":"10.1155\/2014\/570241","type":"journal-article","created":{"date-parts":[[2014,4,30]],"date-time":"2014-04-30T17:03:43Z","timestamp":1398877423000},"page":"1-9","source":"Crossref","is-referenced-by-count":5,"title":["Ferric Carboxymaltose-Mediated Attenuation of Doxorubicin-Induced Cardiotoxicity in an Iron Deficiency Rat Model"],"prefix":"10.1155","volume":"2014","author":[{"given":"Jorge Eduardo","family":"Toblli","sequence":"first","affiliation":[{"name":"Hospital Alem\u00e1n, Laboratory of Experimental Medicine, School of Medicine, Avenue Pueyrredon 1640, 1118 Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Rivas","sequence":"additional","affiliation":[{"name":"Hospital Alem\u00e1n, Laboratory of Experimental Medicine, School of Medicine, Avenue Pueyrredon 1640, 1118 Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Cao","sequence":"additional","affiliation":[{"name":"Hospital Alem\u00e1n, Laboratory of Experimental Medicine, School of Medicine, Avenue Pueyrredon 1640, 1118 Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Fernando","family":"Giani","sequence":"additional","affiliation":[{"name":"Instituto de Qu\u00edmica y Fisicoqu\u00edmica Biol\u00f3gica (UBA-CONICET), Facultad de Farmacia y Bioqu\u00edmica, University of Buenos Aires, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0794-1105","authenticated-orcid":true,"given":"Felix","family":"Funk","sequence":"additional","affiliation":[{"name":"Vifor (International) AG, Rechenstrasse 37, 9014 St. Gallen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6723-8441","authenticated-orcid":true,"given":"Lee","family":"Mizzen","sequence":"additional","affiliation":[{"name":"Vifor Pharma, 1203-4464 Markham Street, Victoria, BC, Canada V8Z 7X8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Pablo","family":"Dominici","sequence":"additional","affiliation":[{"name":"Instituto de Qu\u00edmica y Fisicoqu\u00edmica Biol\u00f3gica (UBA-CONICET), Facultad de Farmacia y Bioqu\u00edmica, University of Buenos Aires, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-337"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.8.8.1039"},{"issue":"2","key":"3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1096\/fasebj.13.2.199","volume":"13","year":"1999","journal-title":"FASEB Journal"},{"issue":"4, supplement 10","key":"4","first-page":"10","volume":"25","year":"1998","journal-title":"Seminars in Oncology"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(90)90088-J"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.06.019"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt118"},{"key":"8","year":"2014"},{"issue":"8","key":"9","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/annonc\/mds112","volume":"23","year":"2012","journal-title":"Annals of Oncology"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh235"},{"issue":"12","key":"11","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P","volume":"91","year":"2001","journal-title":"Cancer"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.9-90005-55"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1042\/CS20040278"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics3010012"},{"issue":"2","key":"15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/0041-008X(85)90284-4","volume":"78","year":"1985","journal-title":"Toxicology and Applied Pharmacology"},{"issue":"4, supplement 10","key":"16","first-page":"15","volume":"25","year":"1998","journal-title":"Seminars in Oncology"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp103"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e328337598c"},{"issue":"8","key":"19","doi-asserted-by":"crossref","first-page":"573","DOI":"10.5414\/CP201692","volume":"50","year":"2012","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"issue":"4","key":"20","first-page":"176","volume":"59","year":"2009","journal-title":"Drug Research"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e328349064c"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60761-756-3_18"},{"key":"23","first-page":"764","volume-title":"Assay of catalase and peroxidase","year":"1955"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.161265"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2008.01019.x"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(98)00076-5"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs224"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006080911"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2008.06.015"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.01.020"},{"issue":"3","key":"31","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0022-2143(96)90095-5","volume":"127","year":"1996","journal-title":"Journal of Laboratory and Clinical Medicine"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1124\/pr.56.2.6"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1124\/mol.105.013383"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908355"},{"key":"35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0869"},{"key":"36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.02.060"},{"key":"37","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics3010012"},{"issue":"11","key":"38","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1093\/ndt\/gfq260","volume":"25","year":"2010","journal-title":"Nephrology, Dialysis, Transplantation"}],"container-title":["Chemotherapy Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/archive\/2014\/570241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/archive\/2014\/570241.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/archive\/2014\/570241.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T13:06:22Z","timestamp":1607519182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/cherp\/2014\/570241\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,30]]},"references-count":38,"alternative-id":["570241","570241"],"URL":"https:\/\/doi.org\/10.1155\/2014\/570241","relation":{},"ISSN":["2090-2107","2090-2115"],"issn-type":[{"value":"2090-2107","type":"print"},{"value":"2090-2115","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,30]]}}}